Sporotrichosis
The saturated solution of potassium iodide (SSKI) has been the first choice for the treatment of lymphocutaneous and fixed cutaneous forms of sporotrichosis since 1900.1,15,16,17 Its efficacy and low cost allowed this drug to be safely used for a long period of time. However, the ease of dosage of itraconazole, which was introduced in the 1990s, caused it to be considered the first-line drug in some centers, although it is more expensive and not different from SSKI in terms of efficacy. In the main international guidelines on the treatment of this disease, the authors classify the different therapeutic options according to levels of evidence and scientific quality. SSKI and itraconazole are at the same level, that is, IIA. Therefore, they are equally effective and indicated as a therapeutic option for the treatment of lymphocutaneous and fixed cutaneous forms of sporotrichosis.
Entomophthoromycoses
Entomophthoromycoses are subcutaneous mycoses caused by zygomycetes of the genus Basiodiobolus and Conidiobolus. They can be treated with SSKI, which is considered the gold standard treatment even when compared to the most recent antifungal drugs. Case reports show satisfactory results even in exuberant cases, with good cure rates.
Other
The use of SSKI has been described in the literature as a therapeutic alternative for the treatment of some infections, especially when it is impossible to use other medications. Surgical procedures such as electrocoagulation, exeresis, surgical drainage, thermotherapy or cryotherapy may often be associated. Here are some indications: chromomycosis, mycetoma, cutaneous nocardiosis, cutaneous cryptococcosis and human pythiosis. Therapeutic success is directly linked to the size and duration of the lesion and to the immunological status of the host.
Inflammatory and immune-mediated dermatoses
The two best indications in this group are neutrophilic dermatoses and panniculitis.1,2 The pathophysiology of pyoderma gangrenosum, Sweet's syndrome and Behçet's disease involves the action of neutrophils. 1 These cells are especially present in early stages, when the intense attraction and toxicity of polymorphonuclear cells produce an exuberant inflammatory response and sterile purulent discharge. Behçet's disease exhibits clear manifestations of this mechanism, such as acne, hypopyon and aseptic meningitis. Potassium iodide has an inhibitory effect on the chemotaxis of neutrophils and on the production of toxic radicals by these cells, which justifies its use in this group of disorders.
It is possible to assume that potassium iodide has an important anti-inflammatory role in panniculitis, since the patients that show better response also present systemic symptoms and increased C-reactive protein. It usually improves fast, with fever, pain and erythema reduction in two days and complete remission in up to two weeks. The main indications are the following: erythema nodosum, nodular vasculitis and subacute nodular migratory panniculitis.
Miscellaneous
Potassium iodide has been successfully used for the treatment of erythema multiforme, even when associated with infection with herpes simplex; granuloma annulare, including reports of good response to widespread cases of the disease; Erythema annulare centrifugum; and Wegener's granulomatosis.
The recommended dose of potassium iodide to treat infectious diseases varies from 4 to 6g/day or 6 to 7.5 g/day for adults, depending on the scientific reference. The pediatric dose is about half or a third of the adult dose.
However, the recommended dose for inflammatory dermatoses is lower. It is approximately 1g/day for adults, taken in three doses.1,27,28
As an expectorant, the syrup is formulated at 2% (20mg/mL) and administered at a dose of 5 mL, 34x /day. 4
To make its use more convenient, potassium iodide is administered in the form of a saturated solution (SSKI).1 A saturated solution should be understood as one in which the addition of any solute will result in its precipitation. Considering the solubility limit for distilled water, which is the vehicle usually used, we found that 1g of the salt to a volume of 0.7 mL of this solvent results in a solution of approximately 1.42 g/mL.4
A discrepancy regarding the dosage of SSKI to be administered is observed in the scientific literature. This can be evidenced in the formulations recommended by WHO or even by some reference books and scientific articles on pharmacology, which define the concentration of the saturated solution of potassium iodide as 1g/mL.4,17,26-31 They probably use already prepared saturated solutions and dilute them to obtain a concentrated solution (not saturated) of 1g/mL. In Brazil, we typically use the pure potassium iodide salt (PA) in the therapeutic formulations.
It is important to have all these considerations in mind before administering the drug to a patient so that the actual dose can be known. Toxicity or absence of therapeutic response is often due to inadequate dosage. Most studies address the number of drops to be administered in the treatment, without even mentioning the characteristics of the solution and the volume of drops used, that is, the amount in grams that is being administered to the patient.
For these reasons, it can be inferred that the knowledge and standardization of the proper use of SSKI are important so that treatment can be tolerable, safe and correct.
When using pure potassium iodide crystals (PA), the correct formula for a final volume of 100 mL is 100 g of salt to 70 mL of distilled water or 50 g of salt to 35 mL of water if the desired final volume is 50 mL.
Considering a standard dropper in which each drop has a volume of 0.05 mL, there will be 0.07 g of KI per drop (1.42 g/mL) in the solution. Thus, by administering 20 drops of the solution 3x/day, the daily intake of potassium iodide is approximately 4g. It is also possible to use the concentrated solution, in which there is 1g of potassium iodide in each mL of water. However, if we consider the same drop volume of 0.05 mL, the daily dose taken by administering 20 drops 3x/day will be 3g.
The studies on dosage recommendation are based on the most classic indication, that is, on the treatment of sporotrichosis. According to the official publication of IDSA (Infectious Diseases Society of America), the recommendation for the treatment of lymphocutaneous or fixed cutaneous sporotrichosis is 40-50 drops 3x/day of a saturated solution, but they do not say how the solution is prepared.18 If it were saturated, the daily total dose would be unbearable, between 8.4 and 10.5 g/day. It is possible that they have considered the concentrated solution, even though the daily dose of 6-7.5g is not always well tolerated.
Another standardization to be reviewed is related to drop volume. A standard dropper usually has 0.05 mL/drop, but there are variations.32 In Brazil, we usually administer 4-6g/day in the treatment of sporotrichosis, which is taken in three doses (Table 2).1,17,26-28 In summary, no matter whether the solution is concentrated or saturated, it is important to know the formulation being used so that the daily dose for inflammatory, infectious or immune-mediated diseases can be adjusted.
The use of KI is contraindicated in cases of previous thyroid diseases such as hypo or hyperthyroidism, presence of nodules and thyroid cancer. Family history of thyroid disease is a relative contraindication. However, positivity for autoantibodies such as anti-TPO antibodies (anti-thyroid peroxidase) and TRAb (TSH receptor antibodies) show a predisposition to autoimmune thyroid diseases that can be triggered by exposure to iodine.1,33
KI is also contraindicated in patients with any type of allergy to iodine.4,28,29,30 Its use should be avoided in patients with chronic renal failure because of the presence of potassium in its formulation and is proscribed in those whose renal function is greatly impaired. Similarly, those using potassium-sparing diuretics or angiotensin-converting-enzyme inhibitors should be closely monitored.1,4,28
It is prudent to avoid the concomitant use of other medications such as lithium, because of its drug interaction, and of medications containing iodine in its formulation such as amiodarone.4,28
Transplant patients and patients with cancer, a history of alcoholic disease, poorly controlled diabetes mellitus and insulin-dependency, autoimmune diseases and immunosuppressive characteristics such as AIDS, and patients who use corticosteroids and immunosuppressive medications should not use this medicine, for its mechanism of action affects the immune system. Active tuberculosis is also included in this group.30
It should not be used by pregnant and lactating women, for it causes neonatal hypothyroidism, thyromegaly, fetal airway obstruction and prolonged labor, being among the category D drugs.1,4,28,30
It should also not be administered to patients with Addison's disease, since they do not only present an autoimmune condition but also changes similar to those that occur with the use of angiotensin-converting-enzyme inhibitors.28
Regarding infectious diseases, KI is not recommended in cases of extensive disease or in cases of involvement of internal organs such as systemic or disseminated cutaneous forms of sporotrichosis, because it is believed that these patients' immune system is impaired.18
Adverse effects, usually mild to moderate, may occur due to the high doses administered, especially for the treatment of infectious skin disorders. They are often related to the digestive system, with a predominance of gastrointestinal intolerance and a metallic or bitter taste in the mouth.1,30
To relieve these symptoms, it is recommended to start the treatment with low doses of the drug, usually five drops of 1.42 mg/mL (0.35 g) three times a day, with daily increases of a drop every time the medicine is taken until the target dosage is reached, for both adults and children.1,4,17,18,29,30 Another recommendation is to take the medicine after meals, with the intake of juice or milk soon afterwards.29 Some pharmacological references recommend mixing the medicine with these drinks.1,17,30 Reducing the dose every time the medicine is taken often eliminates the gastrointestinal complaint without reducing its efficacy.
Due to the presence of large amounts of iodine in the drug, it is possible that it has some effects on the metabolism of the thyroid. There is a physiological mechanism of autoregulation in the human body that aims to keep the pool of stored iodine balanced. Thus, an excess of iodine causes an acute inhibitory effect with a temporary increase in TSH called adaptive block. However, there are escape mechanisms that help maintain the normal function of the gland.1,10
The Wolff-Chaikoff phenomenon is described as an interruption in the thyroid hormone synthesis due to the inability of the thyroid to overcome the acute inhibitory effect resulting from inefficient escape mechanisms in individuals with underlying thyroid disorders, especially Hashimoto's thyroiditis. In these cases, there is axis suppression and increased TSH levels, with consequent hypothyroidism (decreased free T4).1,33
On the other hand, if the patient presents autonomous hormone production in toxic multinodular goiter or in Graves' disease, there may be hyperthyroidism or thyrotoxicosis, which is called Jod-Basedow.1,33
Other adverse effects are occasionally found in the scientific literature, such as acneiform eruption, dermatitis herpetiformis, pustular psoriasis, bullous pemphigoid and iododerma, possibly related to the action on the chemotaxis of polymorphonuclear cells, with iododerma being the most frequent condition in patients with underlying systemic diseases. The syndrome caused by iodine poisoning is called iodism. It is characterized by conjunctival hyperemia, lacrimation, blurred vision, rhinorrhea and sialorrhea.1,28,30
As with any drug, allergic reactions such as urticaria and angioedema should be considered.1,29 Cases of congestive heart failure with pulmonary edema and cases of toxicity related to potassium iodine, such as renal dysfunction, cardiac arrhythmia and metabolic acidosis, have been described.30,34,35 Headaches, arthralgia and prolonged fever have also been reported.1,30
CONCLUSION
Despite being used in Medicine for over a century, potassium iodine remains a good therapeutic option for the treatment of several dermatoses as a drug of first or second choice and may be part of the dermatologist's therapeutic arsenal. When treatment with potassium iodide is considered, it is important to know the exact dose being administered, since the toxicity is directly related to dosage and not to the drug. This involves knowing the formulation being used and the effective dose per drop (in grams) for each individual and therapeutic indication. The toxicity of a drug alone does not constitute a reason to abandon its use, since deeper knowledge of the drug may generate benefits to the patient who does not have access or cannot use other medications due to high cost, adverse effects, drug interactions or even therapeutic failure, in case adverse effects can be controlled, of course. Simply recommending the number of drops may lead to misuse and undue dose administration with risks for the patient.
* Work conducted at the Mycology Laboratory of the Dermatology Service, Hospital Universitário Pedro Ernesto (Pedro Hernesto University Hospital), Universidade do Estado do Rio de Janeiro (Rio de Janeiro State University) - HUPE-UERJ - Rio de Janeiro (RJ), Brazil.
Conflict of interest: None
Financial Support: None